NO985558L - Ny forbedret formulering for behandling av tromboembolisme - Google Patents

Ny forbedret formulering for behandling av tromboembolisme

Info

Publication number
NO985558L
NO985558L NO985558A NO985558A NO985558L NO 985558 L NO985558 L NO 985558L NO 985558 A NO985558 A NO 985558A NO 985558 A NO985558 A NO 985558A NO 985558 L NO985558 L NO 985558L
Authority
NO
Norway
Prior art keywords
treatment
thromboembolism
formulation
new improved
improved formulation
Prior art date
Application number
NO985558A
Other languages
English (en)
Norwegian (no)
Other versions
NO985558D0 (no
Inventor
Froth Jan-Erik L
Lennart Lindfors
Anna-Lena Ungell
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO985558D0 publication Critical patent/NO985558D0/no
Publication of NO985558L publication Critical patent/NO985558L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO985558A 1996-05-31 1998-11-27 Ny forbedret formulering for behandling av tromboembolisme NO985558L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602145A SE9602145D0 (sv) 1996-05-31 1996-05-31 New improved formulation for treatment of thromboembolism
PCT/SE1997/000914 WO1997045138A1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism

Publications (2)

Publication Number Publication Date
NO985558D0 NO985558D0 (no) 1998-11-27
NO985558L true NO985558L (no) 1998-11-27

Family

ID=20402816

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985558A NO985558L (no) 1996-05-31 1998-11-27 Ny forbedret formulering for behandling av tromboembolisme

Country Status (14)

Country Link
US (1) US6673365B1 (de)
EP (1) EP1015022B1 (de)
JP (1) JP2000511526A (de)
AR (1) AR013569A1 (de)
AT (1) ATE284706T1 (de)
AU (1) AU722450B2 (de)
CA (1) CA2253410A1 (de)
DE (1) DE69731981T2 (de)
ID (1) ID19472A (de)
NO (1) NO985558L (de)
NZ (1) NZ332788A (de)
SE (1) SE9602145D0 (de)
WO (1) WO1997045138A1 (de)
ZA (1) ZA974386B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464175A (en) * 1982-08-25 1984-08-07 Altman Alan R Multipurpose tamponade and thrombosclerotherapy tube
US4568545A (en) * 1982-10-02 1986-02-04 Amano Seiyaku Kabushiki Kaisha Thrombolytic agent
KR950703333A (ko) 1992-10-02 1995-09-20 알렌 제이. 스피겔 비이온계 계면활성제 함유 약학 조성물(Pharmaceutical Compositions Containing Nonionic Surfactants)
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation

Also Published As

Publication number Publication date
AU3111597A (en) 1998-01-05
ZA974386B (en) 1997-12-01
ID19472A (id) 1998-07-16
DE69731981T2 (de) 2005-12-22
CA2253410A1 (en) 1997-12-04
EP1015022B1 (de) 2004-12-15
DE69731981D1 (de) 2005-01-20
AR013569A1 (es) 2001-01-10
NO985558D0 (no) 1998-11-27
JP2000511526A (ja) 2000-09-05
NZ332788A (en) 2000-05-26
SE9602145D0 (sv) 1996-05-31
WO1997045138A1 (en) 1997-12-04
ATE284706T1 (de) 2005-01-15
AU722450B2 (en) 2000-08-03
EP1015022A1 (de) 2000-07-05
US6673365B1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
NO972475L (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
NO944997L (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
DK1011673T3 (da) Hidtil ukendt metode til behandling af nidom
RU94022017A (ru) Способ лечения акне или псевдофолликулита бороды, способ получения композиции, применение ингибитора фермента орнитиндекарбоксилазы для лечения акне или псевдофолликулита бороды
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
FI915093A0 (fi) Sackarinderivat anvaendbara som inhibitorer foer proteolytiskt enzym och deras framstaellning.
MX9701514A (es) Limpieza, desinfeccion y preparacion de lentes de contacto.
NO994822L (no) Immunotolerant protrombinkomplekspreparat
WO2002028434A3 (en) Use of a ppar delta activator for treating inflammatory conditions
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
EE03517B1 (et) ACE-inhibiitorite uus meditsiiniline kasutamine düspeptiliste sümptomite raviks
EE03804B1 (et) Karboanhüdraasi inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nähtud kollatähni turseravimiseks
NO984920L (no) Preparater omfattende en nitronforbindelse for anvendelse ved behandling av okulµr inflammasjon
IS3577A7 (is) Aðferð til að sótthreinsa og um leið staðreyna árangur sótthreinsunarinnar, ásamt efni til þess
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism
WO2001034546A3 (en) Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
DK0968174T3 (da) Optisk aktiv 2-aminotetralin, fremgangsmåde til dets fremstilling og farmaceutiske præparater indeholdende selv samme, effektiv til forebyggelse og behandling af septisk chok
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
RU96119673A (ru) Способ лечения болевого синдрома
ITMI922657A1 (it) Composizione terapeutica per uso rettale a base di flunisolide e/o dei relativi esteri per il trattamento di disordini intestinali a carattere infiammatorio

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application